Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Sana Biotechnology Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.36 (market cap $77.43B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 92.5× Sana Biotechnology Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and Sana Biotechnology Inc for 23 Days on average.
| MDLZ | SANA | |
|---|---|---|
Market Cap | $77.43B | $836.71M |
Volume | 7,695,104 | 4,507,444 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $5.92 |
52-Week Low | $51.51 | $2.68 |
Typical Hold Time | 107 Days | 23 Days |
Enterprise Value | $97.78B | $749.96M |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.39, up 1.7% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $0.73 exceeding expectations, supported by $38.54B revenue in 2025. Recent dividend increase to $0.52 per share and positive media coverage highlight management's confidence in cash flow stability. Valuation metrics include P/E of 22.22 and P/S of 1.97, trading below the consensus price target of $70.29.
MDLZ presents a compelling investment case with 76% analyst buy ratings and 16% upside to target, though cocoa cost pressures and margin compression from 13.76% in 2023 to 6.36% in 2025 pose near-term risks. The company's global brand portfolio and emerging market growth provide long-term stability, but investors should monitor commodity inflation's impact on profitability amid current neutral oscillator signals.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
